image dons

I make a donation

ARCHIPELAGO

Effect of irbesartan and enalapril in non-ST segment elevation acute coronary syndrome

Terminée

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

logo étude

objectif

International multicentric trial aiming to compare, over 2 months, the effect of a treatment with irbesartan to a treatment with enalapril on cardio-vascular markers in patients with acute coronary syndrome without ST segment elevation.

date de réalisation

2006

nombre de patients

429

nombre de centres participants

63 centers in 11 countries

type de financement

Private (Sanofi-Aventis et BMS)

Référence

NCT00296218

Randomized Comparison of a Two-month Regimen of Irbesartan Versus Enalapril on Cardiovascular Markers in Patients With Acute Coronary Syndrome Without ST Segment Elevation (ARCHIPELAGO)

Study Description

The main objective of this study is to assess if a two-month regimen of irbesartan in patients hospitalized for acute coronary syndrome without ST segment elevation can reduce inflammation markers (ie hsCRP), in comparison to a similar regimen of enalapril.

source clinicaltrials.gov

Publications

  • Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study
    Gilles Montalescot, Helmut Drexler, Richard Gallo, Thomas Pearson, Martin Thoenes, Deepak L Bhatt
    Publicated in European Heart Journal
  • Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event rates
    Farzin Beygui, Johanne Silvain, Ana Pena, Anne Bellemain-Appaix, Jean-Philippe Collet, Helmut Drexler, Deepak Bhatt, Eric Vicaut, Gilles Montalescot
    Publicated in The American Journal of Cardiology

Autres études

+

AMUNDSEN

En cours


A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....
+

ANCHOR

En cours


Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients
+

AMUNDSEN

En cours


A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....